Absolutely...that's exactly what they do ...bash us and
Absolutely...that's exactly what they do ...bash us and then go buy under
$ 2.70....been this way pretty much since the blood letting of last June
...I still believe in the CSP in Philippines...and of course the size of what India alone could be would dwarf anything the bashers could dispute.
..I personally hope that the executive team get these locked and loaded before they keep telling us ..."things are happening" !!!
.....versus ." we just got an order for this , or we just got approval for that"....at that point the medical ecosystem should kick in and begin the ramp up of our product with or without our own country getting on board
...I don't care what Nader has said about the FDA ...he has to be nice to them , even though they have been slow rolling us for many years
....Gilead doctors on the DSMB...hello everyone ...if you don't believe in these theories then ok disregard it ....
I agree with Seeth and Jay ...there is no reason for the FDA not to grant an EUA while more results are coming in ...and we all are supposed to think this is just government bureacracy ....please....
.....GILEAD and their friends in low places will continue to try and stop this from getting out there ...especially when you look at the COVD and HIV opportunity to cut into their dominance ...
a good friend of mine was in the hospital for the last three weeks they pumped him full of remdeathisnear for weeks multiple times ....when we asked the doctors administering him this drug for two weeks 4-5 times " what about Leronlimab???" their response was ...we don't use any experimental pharmaceuticals ever , and never will ....
The family was telling the docs and hospital they would sign anything they wanted for liability issues and the hospital would not even consider it....GILD is selling tons of a drug that does nothing to the severe critical population and getting billions already for that despicable behavior ..."oh let's take a drug we developed for ebola and sell it to Fauci and the rest of our cronies for this new virus !!!....remember AZT ...we can do it again and make billions !!! "
the doctors tending my friend obviously never heard of leronlimab and no one is getting them to do any reading about it ..
.......how sad it is until the real word of its efficacy and safety is reported many times and one of the countries we are talking to takes the next step.....
sorry for the Monday morning rant and the pumping of conspiracy theories ...but come on ...at some point this dam has to break ...and my comments have no political over tones at all !!!
I hope and pray soon CYDY will be vindicated ....
GLTA
14
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....
Continue Reading
Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...
Continue Reading
Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...
Continue Reading
KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...
Continue Reading
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...
Continue Reading
New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...
Continue Reading
A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...
Continue Reading
Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...
Continue Reading
Top 5 Most Recently Viewed Articles
CNX Resources Corporation Financial Update CNX Resources Corporation (NYSE: CNX) is gearing up to announce its financial outcomes for the third quarter of 2024. This announcement is scheduled for 6:45 a.m. Eastern Time on a Thursday morning toward the end of October. During this time, CNX will also share essential materials, including remarks prepared for the quarter,...
Continue Reading
Strengthening Research Cooperation Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) has officially expanded its strategic partnership with École Polytechnique, aiming for a more profound collaboration in artificial intelligence (AI) research. This new Collaborative Research Agreement is a significant step towards enhancing research capabilities in both...
Continue Reading
The Growing Marine Collagen Market The marine collagen market is set to experience significant growth in the coming years. As consumer awareness around health and beauty continues to rise, we see a shift in preference towards marine collagen, thanks to its impressive bioavailability and sustainable sourcing methods. Recent analyses reveal that this sector is predicted to...
Continue Reading
Exciting Financial Insights Awaiting from BioLife Solutions BioLife Solutions, Inc. (NASDAQ: BLFS) has announced that it will disclose its first quarter 2025 financial results, marking an important update for investors and stakeholders alike. This revelation is set to occur after the market closes, creating anticipation among those closely monitoring the company’s...
Continue Reading
FuboTV Reports Unprecedented Subscriber Growth FuboTV (NYSE: FUBO) has recently made headlines as it recorded the highest-ever growth in its North American subscriber base. This achievement highlights the company’s potential in the competitive streaming industry. The stock saw a notable increase on the day the company announced its earnings for the third quarter....
Continue Reading